Skip to content

A clinical study evaluating the diagnostic efficacy of 68Ga-Trop2 compared to 18F-FDG PET/CT in the diagnosis of papillary thyroid carcinoma

A clinical study evaluating the diagnostic efficacy of 68Ga-Trop2 compared to 18F-FDG PET/CT in the diagnosis of papillary thyroid carcinoma

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121650
Enrollment
Unknown
Registered
2026-04-01
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid cancer

Interventions

Index test:68Ga-Trop2 PET/CT

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Aged >=18, male or female; (2) Patients with newly diagnosed papillary thyroid cancer or patients with elevated thyroid globulin after total thyroidectomy/I-131 treatment: a) Patients with newly diagnosed papillary thyroid cancer who have been confirmed by pathological examination and have not received any treatment; or b) Patients with elevated serum Tg (>=1 ng/mL) after total thyroidectomy for previous papillary thyroid cancer or after iodine treatment for papillary thyroid cancer; (3) Patients with an estimated survival time of >3 months as determined by the doctor; (4) Patients who voluntarily sign the informed consent form; (5) Patients who are willing and able to follow the study protocol.

Exclusion criteria

Exclusion criteria: (1) Those who cannot tolerate intravenous administration (such as history of fainting from acupuncture or blood); (2) Those who, in the opinion of the researcher, are not suitable for or unable to complete imaging examinations such as PET due to special reasons, including claustrophobia, radiophobia, etc.; (3) Practitioners who need to be exposed to radioactive conditions for a long time; (4) Those with severe diseases of the heart, kidney, lung, blood vessels, nerves, nervous system, immune deficiency diseases, and hepatitis/cirrhosis; (5) Those with other conditions that, in the opinion of the researcher, make them unsuitable for participating in this study.

Design outcomes

Primary

MeasureTime frame
SUVmax (Standardized Uptake Value max);sensitivity;specificity;accuracy;

Countries

China

Contacts

Public ContactShaoli Song

Fudan University Shanghai Cancer Center

shaoli-song@163.com+86 138 1660 8573

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026